Germline variants and polygenic risk models have been developed to predict IDH tumor mutation status.8,9 If a lesion is likely a glioma, then an IDH mutation polygenic model would allow for prediction of molecular subtype prior to surgery using a noninvasive blood-based assay. The gene discussed is IDH2; the disease is central nervous system cancer.